Stifel Maintains Buy Rating for argenx: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Stifel has reaffirmed its Buy rating on argenx (NASDAQ:ARGX) and increased its price target from $557.00 to $560.00. Despite the positive outlook, argenx shares have fallen 1.05% in the last 24 hours to $458.16. The new price target suggests a potential upside of 22.23%. Argenx specializes in antibody engineering for rare autoimmune diseases, with its drug Vyvgart approved in the U.S., Europe, and Japan.
December 18, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel maintains a Buy rating on argenx and raises its price target to $560, indicating a potential 22.23% upside from the current price.
Stifel's maintained Buy rating and increased price target for argenx reflect a positive outlook on the company's stock, which could influence investor sentiment and drive the stock price up in the short term. The recent dip in share price may present a buying opportunity if investors align with Stifel's analysis.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100